VCCC Alliance Precision Oncology Forum
Understanding the evolution of high-grade serous ovarian cancers
15 September 2023
High-grade serous ovarian cancer is the most common subtype of ovarian cancer. For the September Precision Oncology Forum, medical oncologist Dr Nikki Burdett will be showcasing her research on understanding the genetic evolution of these cancers.
High-grade serous ovarian cancer is the most common subtype of ovarian cancer. The five-year survival for patients with this disease is 35-40%, improving little over the past few decades.
These multi-disciplinary style forums provide opportunities to discuss new research topics in Precision Oncology, as well as interesting and novel cases illustrating the clinical implications of molecular pathology and targeted therapies. Cases are discussed on an individual, de-identified basis. This forum also features an educational presentation.
The VCCC Alliance Precision Oncology Forum is chaired by Dr Stephen Luen, Medical Oncologist at Peter MacCallum Cancer Centre.
Aim: To showcase research on understanding the genetic evolution of high-grade serous ovarian cancer.
Learning Objective: In this session, you will gain a greater insight into the genetic evolution of high-grade serous ovarian cancer.
Dr Nikki Burdett
Nikki Burdett is a clinician researcher at Peter MacCallum Cancer Centre, focused on improving the lives of individuals with gynaecological cancers. Her research focuses on understanding and manipulating the molecular biology of ovarian cancer to subvert the development of resistance to therapy. She completed her PhD with Dr Liz Christie and Professor David Bowtell, investigating diverse mechanisms of acquired resistance in high grade serous ovarian cancer, and continues to build on these insights in Dr Christie’s laboratory.
Resource details
This course is brought to you by
